JNCE
Jounce Therapeutics, Inc.
Set alert
1.88 0.00 0.00%
1.88 Day range 1.93
52-week range unavailable
- Open
- 1.92
- Prev close
- 1.88
- Mkt cap
- 101.59M
- Vol
- 11.60M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.88
- High
- 1.93
- Forward P/E
- -1.83
- Beta
- 0.75
- Short ratio
- 0.48
- Inst. own
- 85.33%
- Dividend
- 0.00
- Ex-div date
- Earnings
- May 4, 2023
- 50-d avg
- 1.64
- 200-d avg
- 1.93
- 1y target
- 2.00
Financial health
Altman Z-Score
0.64 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
3 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
Valuation
P/E -1.1×
FY 2014 5y median -4.0× FY 2022
P/S 0.7×
FY 2014 5y median 2.0× FY 2022
P/B 0.3×
FY 2014 5y median 1.2× FY 2022
P/FCF -1.9×
FY 2014 5y median -5.0× FY 2022
EV/EBITDA 1.7×
FY 2014 5y median -2.6× FY 2022
EV/Sales -1.0×
FY 2014 5y median 1.7× FY 2022
FCF Yield -51.9%
FY 2014 5y median -20.1% FY 2022
Profitability
Gross Margin 100.0%
FY 2014 5y median 100.0% FY 2022
Operating Margin -63.7%
FY 2014 5y median -63.7% FY 2022
Net Margin -62.1%
FY 2014 5y median -62.1% FY 2022
ROE -27.8%
FY 2014 5y median -26.3% FY 2022
ROIC -27.0%
FY 2014 5y median -21.0% FY 2022
ROA -24.0%
FY 2014 5y median -18.0% FY 2022
Growth (YoY)
Revenue 204.8%
FY 2014 FY 2022
Operating Income 42.6%
FY 2014 FY 2022
EPS (diluted) 45.6%
FY 2014 FY 2022
Free Cash Flow 64.5%
FY 2014 FY 2022
Financial Health
Current Ratio 8.4×
FY 2014 5y median 10.1× FY 2022
Quick Ratio 8.4×
FY 2014 5y median 10.1× FY 2022
Debt / Equity 0.1×
FY 2014 5y median 0.1× FY 2022
Net Debt / EBITDA 2.8×
FY 2014 5y median 2.0× FY 2022
Interest Coverage 0.0×
FY 2014 5y median 0.0× FY 2022
Dividends
Dividend Yield 0.0%
FY 2014 5y median 0.0% FY 2022
Payout Ratio 0.0%
FY 2014 5y median 0.0% FY 2022
Annual · latest fiscal year ends 2022-12-31